A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,501–1,600 of 3,967
Yu, S., Long, Y., Li, D., Shi, A., Deng, J., Ma, Y., Wen, J., Li, X., Zhang, Y., Liu, S., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106339 · Cited by 21
Egea-Zorrilla, A., Vera, L., Sáez, B., & Pardo–Saganta, A. (2022) · Cells · doi:10.3390/cells11162595 · Cited by 22
Lv, X., Liu, S., Liu, C., Li, Y., Zhang, T., Qi, J., Li, K., Hua, F., Cui, B., Zhang, X., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.008 · Cited by 22
Molecular Mechanisms in Genetic Aortopathy–Signaling Pathways and Potential Interventions
Dong, C. X., Malecki, C., Robertson, E., Hambly, B. D., & Jeremy, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021795 · Cited by 27
“An inhibitor of TGF-β and downstream signaling mechanisms, pirfenidone, was FDA approved in 2014 for the treatment of idiopathic pulmonary fibrosis, indicating the therapeutic potential of inhibiting TGF-β signaling in a clinical setting [304,305].”
BackgroundNakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 22
“PFD is the first drug shown to alleviate the reduced respiratory function and to extend the survival of patients with IPF [44,45].”
BackgroundMethodCeribelli, A., Tonutti, A., Isailovic, N., Santis, M. D., & Selmi, C. F. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1068402 · Cited by 24
“Pirfenidone is an antifibrotic drug currently approved for the treatment of idiopathic pulmonary fibrosis (75) and the drug acts by down regulating pro-fibrotic signaling pathways, molecules, and cells, although precise molecular mechanisms are still to be explored (76).”
BackgroundKoh, S. Y., Lee, J. H., Park, H., & Goo, J. M. (2023) · European Radiology · doi:10.1007/s00330-023-10483-9 · Cited by 24
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Hu, J.-P., Teng, J., Hui, S., & Liang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29486 · Cited by 26
“Despite advances in understanding fibrosis mechanisms and treatments, only a few therapies are available that marginally decelerate fibrosis progression [14,15].”
BackgroundShao, M., Qiu, Y., Shen, M., Liu, W. Q., Feng, D., Luo, Z., & Zhou, Y. (2024) · The FASEB Journal · doi:10.1096/fj.202302547rr · Cited by 27
Delineating, Imaging, and Assessing Pulmonary Fibrosis Remodeling via Collagen Hybridization
Zhao, J., Yu, W., Zhou, D., Liu, Y., Wei, J., Bi, L., Zhao, S., He, J., Liu, J., Su, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c06139 · Cited by 25
Wilson, K. C., & Raghu, G. (2015) · European Respiratory Journal · doi:10.1183/13993003.01335-2015 · Cited by 19
Kimman, M., Rotteveel, A. H., Wijsenbeek, M. S., Mostard, R. L. M., Tak, N. C., van Jaarsveld, X., Storm, M., Wijnsma, K. L., Gelens, M., van de Kar, N. C. A. J., et al. (2017) · Patient · doi:10.1007/s40271-017-0234-z · Cited by 22
Elinoff, J. M., Agarwal, R., Barnett, C. F., Benza, R. L., Cuttica, M. J., Gharib, A. M., Gray, M. P., Hassoun, P. M., Hemnes, A. R., Humbert, M. J. C., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-2093pp · Cited by 24
Unclassifiable interstitial lung disease: from phenotyping to possible treatments
Guler, S. A., & Ryerson, C. J. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000509 · Cited by 24
Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors
Terashima, H., Aonuma, M., Tsuchida, H., Sugimoto, K., Yokoyama, M., & Kato, M. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.11.005 · Cited by 20
Microenvironment-Responsive Small-Molecule Probe for Pulmonary Fibrosis Detection
Dong, Y., Li, X., Chen, Q., Guo, R., Tang, B., Kan, W., Zhang, W., Hu, Y., Li, J. X., Zang, Y., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02264 · Cited by 20
Occupational exposures and idiopathic pulmonary fibrosis
Walters, G. I. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000610 · Cited by 22
Sekihara, K., Aokage, K., Miyoshi, T., Tane, K., Ishii, G., & Tsuboi, M. (2020) · Surgery Today · doi:10.1007/s00595-020-01978-9 · Cited by 23
Krauss, E., Tello, S., Wilhelm, J., Schmidt, J., Stoehr, M., Seeger, W., Dartsch, R. C., Crestani, B., & Günther, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113763 · Cited by 23
“The confirmatory phase III trial PIPF-016 (ASCEND) was conducted at the request of the USA Food and Drug Administration (FDA) with the results published in 2014 [21].”
MethodResultChung, J. H., Adegunsoye, A., Cannon, B., Vij, R., Oldham, J. M., King, C. S., Montner, S. M., Thirkateh, P., Barnett, S. D., Karwoski, R. A., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122663 · Cited by 24
Self-citationMa, Y., Zhou, R., & Wu, Q. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-1836 · Cited by 22
Iyoda, A., Azuma, Y., Sakamoto, S., Homma, S. A., & Sano, A. (2021) · Surgery Today · doi:10.1007/s00595-021-02343-0 · Cited by 20
Guler, S. A., Clarenbach, C. F., Brutsche, M. H., Hostettler, K., Brill, A., Schertel, A., Geiser, T., & Funke-Chambour, M. (2021) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-211858 · Cited by 19
Antibody-based therapies for idiopathic pulmonary fibrosis
Sgalla, G., Flore, M., Siciliano, M., & Richeldi, L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1735346 · Cited by 22
“proved to be safe and effective therapeutic options [6,7] and were approved for use in patients with IPF by regulatory”
BackgroundSupplemental Oxygen Therapy in Interstitial Lung Disease: A Narrative Review
Clark, K. P., Degenholtz, H. B., Lindell, K. O., & Kass, D. J. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202304-391cme · Cited by 23
Isshiki, T., Sakamoto, S., Yamasaki, A., Shimizu, H., Miyoshi, S., Nakamura, Y., Homma, S., & Kishi, K. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106551 · Cited by 19
Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
Haynes, Z. A., Chandel, A., & King, C. S. (2023) · Cells · doi:10.3390/cells12192394 · Cited by 22
“present with a fibrotic ILD, antifibrotic therapy with pirfenidone or nintedanib should be offered to slow disease progression and mitigate the impacts of worsening disease [62,63].”
BackgroundPyruvate metabolism dictates fibroblast sensitivity to GLS1 inhibition during fibrogenesis
Contento, G., Wilson, J.-A. A. M., Selvarajah, B., Platé, M., Guillotin, D., Morales, V., Trevisani, M., Pitozzi, V., Bianchi, K., & Chambers, R. C. (2024) · JCI Insight · doi:10.1172/jci.insight.178453 · Cited by 23
Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective
Wang, X., Xu, X., Hou, Y., Zhang, H., Han, W., Sun, J., & Li, F. (2025) · Respiratory Research · doi:10.1186/s12931-025-03270-1 · Cited by 21
Neri, T., Lombardi, S., Faìta, F., Petrini, S., Balìa, C., Scalise, V., Pedrinelli, R., Paggiaro, P., & Celi, A. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.05.003 · Cited by 19
LANCASTER, L. H., Morrison, L. D., Auais, A., Ding, B., Iqbal, A., Polman, B., & Flaherty, K. R. (2017) · Pulmonary Therapy · doi:10.1007/s41030-017-0049-z · Cited by 20
Self-citationA Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Prasse, A., Ramaswamy, M., Mohan, S., Pan, L., Kenwright, A., Neighbors, M., Belloni, P., & LaCamera, P. P. (2019) · Pulmonary Therapy · doi:10.1007/s41030-019-0096-8 · Cited by 20
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Kreuter, M., Lederer, D. J., Cottin, V., Kahn, N. C., Ley, B., Vancheri, C., Weycker, D. A., Atwood, M., Kirchgaessler, K.-U., & Ryerson, C. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.01188-2019 · Cited by 21
Self-citationBoesch, M., Baty, F., Brutsche, M. H., Tamm, M., Roux, J., Knudsen, L., Gazdhar, A., Geiser, T., Khan, P., & Hostettler, K. (2020) · Respiratory Research · doi:10.1186/s12931-020-01414-z · Cited by 20
Diagnosis and Management of Fibrotic Interstitial Lung Diseases
Collins, B. F., & Luppi, F. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.008 · Cited by 22
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98161-y · Cited by 21
Koo, C. W., Larson, N. B., Parris-Skeete, C., Karwoski, R. A., Kalra, S., Bartholmai, B. J., & Carmona, E. M. (2021) · Clinical Radiology · doi:10.1016/j.crad.2021.11.006 · Cited by 21
Wilfong, E. M., & Aggarwal, R. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211060907 · Cited by 22
Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature
Dolivo, D. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02194-3 · Cited by 19
Yamakawa, H., Toyoda, Y., Baba, T., Kishaba, T., Fukuda, T., Takemura, T., & Kuwano, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133835 · Cited by 23
Diagnosis and management of idiopathic pulmonary fibrosis
Joshi, V. V., & Nagji, Z. (2022) · Prescriber · doi:10.1002/psb.1998 · Cited by 19
Liu, J., Cao, L., Li, Y., Deng, P., Pan, P., Hu, C., & Yang, H. (2022) · Human Cell · doi:10.1007/s13577-022-00766-6 · Cited by 20
Dysregulated Cell–Cell Communication Characterizes Pulmonary Fibrosis
Kurche, J. S., Stancil, I. T., Michalski, J. E., Yang, I. V., & Schwartz, D. A. (2022) · Cells · doi:10.3390/cells11203319 · Cited by 19
Xiong, J., Duan, J., Jiang, N., Zhang, C., Zhong, W., Yang, J., Liu, Y., Su, F., Zhou, Y., Li, D., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109339 · Cited by 20
Fukihara, J., & Kondoh, Y. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.05.007 · Cited by 24
p38γ MAPK Inflammatory and Metabolic Signaling in Physiology and Disease
Qi, X.-M., & Chen, G. (2023) · Cells · doi:10.3390/cells12131674 · Cited by 27
Lee, S. Y., Park, S., Lee, S., Kim, H., Kwon, J.-H., Yoo, J., Kim, K., Park, M. S., Lee, C. G., Elias, J. A., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01066-1 · Cited by 26
Zhao, R., Xie, B., Wang, X., Zhang, X., Ren, Y., Wang, C., & Dai, H. (2024) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2024.102287 · Cited by 24
Adegunsoye, A., BACHMAN, W. R. M., Flaherty, K. R., Li, Z., & Gupta, S. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202309-797oc · Cited by 20
Lee, H., Kim, S. Y., Park, Y. S., Choi, S. M., Lee, J. H., & Park, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-59649-5 · Cited by 25
Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis
Leuchte, H. H., Mernitz, P., Baezner, C. J., Baumgartner, R., von Wulffen, W., Neurohr, C., & Behr, J. (2015) · Respiration · doi:10.1159/000441302 · Cited by 17
Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey
Cottin, V., Bergot, E., BOURDIN, A. A., Cadranel, J. L., Camus, P., Crestani, B., Dalphin, J., Delaval, P., Dromer, C., Israël‐Biet, D., et al. (2015) · ERJ Open Research · doi:10.1183/23120541.00032-2015 · Cited by 19
Kreuter, M., Wijsenbeek, M. S., Vašáková, M., Spagnolo, P., Kolb, M. R. J., Costabel, U., Weycker, D. A., Kirchgaessler, K.-U., & Maher, T. M. (2016) · European Respiratory Journal · doi:10.1183/13993003.01482-2016 · Cited by 22
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.02384-2016 · Cited by 19
Diffuse parenchymal lung disease
Tomassetti, S., Ravaglia, C., & Poletti, V. E. (2017) · European Respiratory Review · doi:10.1183/16000617.0004-2017 · Cited by 18
Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014
Algranti, E., Saito, C. A., Silva, D. R. M. E., Carneiro, A. P. S., & Bussacos, M. A. (2017) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562017000000035 · Cited by 22
Hammond, M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., Stirling, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2453-6 · Cited by 20
Hutchinson, J. P., Hubbard, R., & Raghu, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.00023-2019 · Cited by 20
“In people with idiopathic pulmonary fibrosis (IPF), treatment with both Pirfenidone and Nintedanib has been shown to reduce the rate of disease progression (1, 2), whereas historical use of immunosuppression was shown in the landmark PANTHER study to be harmful (3).”
BackgroundPirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation
Veit, T., Leuschner, G., Sisic, A., Ceelen, F., Munker, D., Schmitzer, M., Weig, T. G., Michel, S. G., Schneider, C. P., Meiser, B., et al. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15378 · Cited by 25
Jouneau, S., Gamez, A. S., Traclet, J., Nunès, H., Marchand-Adam, S., Kessler, R., Israël‐Biet, D., Borie, R., Strombom, I., Scalori, A., et al. (2019) · Respiration · doi:10.1159/000496735 · Cited by 20
Idiopathic pulmonary fibrosis: the radiologist’s role in making the diagnosis
Mohning, M. P., Richards, J. C., & Huie, T. J. (2019) · British Journal of Radiology · doi:10.1259/bjr.20181003 · Cited by 23
Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-β1/Smad Pathway
Yao, H., Wei, S., Xiang, Y., Wu, Z., Liu, W., Wang, B., Li, X., Xu, H., Zhao, J., & Gao, Y. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/5124026 · Cited by 24
Ji, K., Jian-ling, M., Liangmin, W., Li, N., Dong, S., & Li-qing, S. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/1752387 · Cited by 22
“Yet, randomized trials have identified some drugs were potentially ineffective or harmful [5, 6], whereas only two, pirfenidone and nintedanib, were proved to be effective disease-modifying therapies for IPF [7, 8].”
BackgroundPulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis
Takei, R., Yamano, Y., Kataoka, K., Yokoyama, T., Matsuda, T., Kimura, T., Furukawa, T., Takahashi, O., Chiba, H., Takahashi, H., et al. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2019.12.010 · Cited by 21
Kim, J. S., Steffen, B. T., Podolanczuk, A. J., Kawut, S. M., Noth, I., Raghu, G., Michos, E. D., Hoffman, E. A., Axelsson, G. T., Guðmundsson, G., et al. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa168 · Cited by 18
Self-citationInhibition of TGFβ improves hematopoietic stem cell niche and ameliorates cancer-related anemia
Wang, B., Wang, Y., Chen, H., Yao, S., Lai, X., Qiu, Y., Cai, J., Huang, Y., Wei, X., Guan, Y., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02120-9 · Cited by 20
Xie, T., Kulur, V., Liu, N., Deng, N., Wang, Y., Rowan, S. C., Yao, C., Huang, G., Liu, X., Taghavifar, F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg6005 · Cited by 24
Self-citationMajewski, S., Szewczyk, K., Jerczyńska, H., Miłkowska-Dymanowska, J., Białas, A. J., Gwadera, Ł., & Piotrowski, W. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.760776 · Cited by 22
Yang, C.-C., Chen, C., Kuo, Y., Ko, C., Wu, W.-J., Liang, C.-H., Yun, C., & Huang, W. (2022) · Diagnostics · doi:10.3390/diagnostics12041002 · Cited by 22
Fernandez, R. J., Gardner, Z., Slovik, K. J., Liberti, D. C., Estep, K. N., Yang, W., Chen, Q., Santini, G. T., Perez, J. V., Root, S., et al. (2022) · eLife · doi:10.7554/elife.64430 · Cited by 20
Kanaan, R., & Strange, C. (2017) · European Respiratory Review · doi:10.1183/16000617.0061-2017 · Cited by 21
Vianello, A., Molena, B., Turato, C., Braccioni, F., Arcaro, G., Paladini, L., Andretta, M., & Saetta, M. P. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1565530 · Cited by 20
Targeting anti-fibrotic pathways in Crohn’s disease – The final frontier?
Ma, C., Jairath, V., Click, B. H., Hirota, S. A., Lu, C., Parker, C. E., & Rieder, F. (2019) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2019.02.005 · Cited by 21
Lee, J. H., Chae, K. J., Park, J., Choi, S. M., Jang, M., Hwang, E. J., Jin, G. Y., & Goo, J. M. (2024) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.230287 · Cited by 22
A new era in the treatment of progressive fibrosing interstitial lung diseases
Denis, A., Tsiri, P., Guiot, J., & Τzouvelekis, Α. (2025) · Breathe · doi:10.1183/20734735.0259-2024 · Cited by 37
King, C. S., & Nathan, S. D. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.034 · Cited by 18
Self-citationIdiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?
Nathan, S. D., Behr, J., Cottin, V., Collard, H. R., Hoeper, M. M., Martínez, F. J., & Wells, A. U. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.003 · Cited by 20
“It is noteworthy that in the pirfenidone (ASCEND/CAPACITY) and the nintedanib (INPULSIS) trials [2,3], patients with a diffusing capacity of the lungs for carbon monoxide (DLco) <30% of predicted were excluded; therefore, the subset of patients whomight have had IPFPH were poorly represented.”
BackgroundSelf-citationΤzouvelekis, Α., Tzilas, V., Papiris, S. A., Aidinis, V., & Bouros, D. E. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.12.002 · Cited by 20
Wijsenbeek, M. S., Bendstrup, E. M., Valenzuela, C., Henry, M. T., Moor, C. C., Bengus, M., Perjesi, A., Gilberg, F., Kirchgaessler, K.-U., & Vancheri, C. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0845-3 · Cited by 20
Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
Moua, T., & Ryu, J. H. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s160248 · Cited by 18
T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
Bonham, C. A., Hrusch, C. L., Blaine, K. M., Manns, S. T., Vij, R., Oldham, J. M., Churpek, M. M., Strek, M. E., Noth, I., & Sperling, A. I. (2019) · Respiratory Medicine X · doi:10.1016/j.yrmex.2019.100002 · Cited by 25
Riddell, P., Kleinerová, J., Eaton, D. A., Healy, D. G., Javadpour, H., McCarthy, J. F., Nölke, L., Redmond, K., & Egan, J. J. (2020) · European Respiratory Journal · doi:10.1183/13993003.02413-2019 · Cited by 19
Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date
Ntolios, P., Steiropoulos, P., Karpathiou, G., Anevlavis, S., Karampitsakos, Τ., Bouros, E., Froudarakis, Μ. E., Bouros, D. E., & Tzouvelekis, A. (2020) · BioDrugs · doi:10.1007/s40259-020-00437-8 · Cited by 20
Determinants of health-related quality of life decline in interstitial lung disease
Maqhuzu, P. N., Szentes, B. L., Kreuter, M., Bahmer, T., Kahn, N. C., Claussen, M., Holle, R., & Schwarzkopf, L. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01570-2 · Cited by 19
Ma, Y., Luo, L., Liu, X., Li, H., Zeng, Z., He, X., Zhan, Z., & Chen, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107593 · Cited by 19
Wijsenbeek, M. S., Bendstrup, E. M., Valenzuela, C., Henry, M. T., Moor, C. C., Jouneau, S., Fois, A. G., Moran‐Mendoza, O., Anees, S., Mirt, M., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01790-y · Cited by 20
Derseh, H. B., Perera, K. U. E., Dewage, S. N. V., Stent, A. W., Koumoundouros, E., Organ, L. A., Pagel, C. N., & Snibson, K. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700902 · Cited by 19
“Although two disease retarding drugs have been approved for IPF in 2014, there is no totally effective pharmacologic treatment currently available that cures the disease (King et al., 2014; Richeldi, 2014; Richeldi et al., 2014).”
BackgroundInsights into the Pathogenesis of Pulmonary Fibrosis from Genetic Diseases
Wang, J. Y., & Young, L. R. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0557tr · Cited by 20
Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease
Choi, J. Y., Song, J. W., & Rhee, C. K. (2022) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2021.0141 · Cited by 22
Contemporary Concise Review 2021: Interstitial lung disease
McCarthy, C., & Keane, M. P. (2022) · Respirology · doi:10.1111/resp.14278 · Cited by 21
Lv, Y., Cai, G.-F., Zeng, P.-P., Dhlamini, Q., Chen, L.-F., Chen, J., Lyu, H., Mohammadi, M. M., Ahmadvand, N., Bellusci, S., et al. (2022) · Cells · doi:10.3390/cells11152396 · Cited by 22
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2022.100948 · Cited by 25
Novel mediators of idiopathic pulmonary fibrosis
Saito, S., Deskin, B., Rehan, M., Yadav, S., Matsunaga, Y., Lasky, J. A., & Thannickal, V. J. (2022) · Clinical Science · doi:10.1042/cs20210878 · Cited by 20
Xu, L., Wang, F., & Luo, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1019915 · Cited by 19
“The main antifibrotic drugs, pirfenidone (King et al., 2014) and nintedanib (Richeldi et al.”
BackgroundLong-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
Levra, S., Guida, G., Sprio, A. E., Crosa, F., Ghio, P. C., Bertolini, F., Carriero, V. M. A., Albera, C., & Ricciardolo, F. L. M. (2022) · Biomedicines · doi:10.3390/biomedicines10123229 · Cited by 20
Choi, M. G., Choi, S. M., Lee, J. H., Kim, J., & Song, J. W. (2022) · Respiratory Research · doi:10.1186/s12931-022-02273-6 · Cited by 17
Association between weight loss and mortality in idiopathic pulmonary fibrosis
Kalininskiy, A., Rackow, A. R., Nagel, D. J., Croft, D. P., Minton, H. M., & Kottmann, R. M. (2022) · Respiratory Research · doi:10.1186/s12931-022-02277-2 · Cited by 21
Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis
Kaul, B., Lee, J. S., Petersen, L. A., McCulloch, C. E., Rosas, I. O., Bandi, V., Zhang, N., DeDent, A. M., Collard, H. R., & Whooley, M. A. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.02.027 · Cited by 18
Gracillin relieves pulmonary fibrosis by suppressing the STAT3 axis
Xie, M., Yang, L., Cheng, J., Qu, H., Gu, Y.-T., Ding, C., Xu, X., Zhao, C., Huang, X., & Wang, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116704 · Cited by 19
Improved Survival of IPF patients Treated With Antifibrotic Drugs Compared With Untreated Patients
Platenburg, M. G. J. P., van Moorsel, C. H. M., Wiertz, I. A., van der Vis, J. J., Vorselaars, A. D. M., Veltkamp, M., & Grutters, J. C. (2023) · Lung · doi:10.1007/s00408-023-00628-4 · Cited by 22
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.